Pathologic Complete Response News Today

The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.

An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.

- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microe...

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.

Immunotherapy given before and after surgery significantly improved outcomes in patients with operable non-small cell lung cancer.

(1) Results support use of Agendias genomic tests to better tailor pre-operative treatment and timing for surgery Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint and BluePrint , and underpin both assays pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at t...